

Key:	>>> ... marks correct (expected) result	N ... number of the results
	> ... marks conditionally correct (acceptable) result	Nrel ... relative number of the results
	± ... marks the result not evaluated	

Test

Sample	Group	N	Result	N _{rel}
--------	-------	---	--------	------------------

Set 1

(560) ANA screening (cell nucleus) - prove

A1	(1) Fluorescent methods	>>>	75 Positive	91 %
	(2) EIA methods	>>>	7 Positive	8,5 %
Total per sample: n = 82		Success: 100 %		
B1	(1) Fluorescent methods	>>>	74 Negative	90 %
			1 Inconclusive result (borderline)	1,2 %
	(2) EIA methods	>>>	7 Negative	8,5 %
Total per sample: n = 82		Success: 99 %		
Total success: 99 %				

(572) ANA screening (cell nucleus) - semi-quantity

A1	(0) Not specified	±	1 titre 40	1,4 %
		±	2 titre 80	2,8 %
		±	2 titre 160	2,8 %
		±	3 titre 320	4,2 %
		±	13 titre 640	18 %
		±	26 titre 1280	37 %
		±	24 titre 2560	34 %
Total per sample: n = 71		Success (only evaluated results): evaluation		
B1	(0) Not specified	±	1 Not specified	1,4 %
		±	50 titre 0 (not measurable)	70 %
		±	12 titre 40	17 %
		±	8 titre 80	11 %
Total per sample: n = 71		Success (only evaluated results): evaluation		

(561) ANA - type of fluorescence - nucleus

A1	(0) Not specified	>>>	71 Centromere pattern	96 %
			2 Centromere pattern; No fluorescence	2,7 %
			1 Centromere pattern; Midbody pattern (MSA-2)	1,4 %
Total per sample: n = 74		Success: 96 %		
B1	(0) Not specified		2 Not specified	2,7 %
		>>>	72 No fluorescence	97 %
Total per sample: n = 74		Success: 97 %		
Total success: 93 %				

(563) ANA screening (cytoplasm) - prove

A1	(1) Fluorescent methods	>>>	71 Negative	97 %
			2 Positive	2,7 %
Total per sample: n = 73		Success: 97 %		
B1	(1) Fluorescent methods	>>>	72 Negative	99 %
			1 Inconclusive result (borderline)	1,4 %
Total per sample: n = 73		Success: 99 %		
Total success: 96 %				

(573) ANA screening (cytoplasm) - semi-quantity

A1	(0) Not specified	±	47 titre 0 (not measurable)	70 %
		±	11 titre 40	16 %
		±	9 titre 80	13 %
Total per sample: n = 67		Success (only evaluated results): evaluation		
B1	(0) Not specified	±	47 titre 0 (not measurable)	70 %
		±	12 titre 40	18 %
		±	8 titre 80	12 %
Total per sample: n = 67		Success (only evaluated results): evaluation		

(564) ANA - type of fluorescence - cytoplasm

A1	(0) Not specified	>>>	68 No fluorescence	97 %
			1 Fine speckled cytoplasmic pattern	1,4 %
			1 Unknown type of fluorescence	1,4 %
Total per sample: n = 70		Success: 97 %		
B1	(0) Not specified	>>>	69 No fluorescence	99 %
			1 Diffusion cytoplasmic picture	1,4 %
Total per sample: n = 70		Success: 99 %		
Total success: 96 %				

EQA round: AIM1/22 - Autoimmunity

Test		N	Result	N _{rel}
Sample	Group			
Set 2				
(565) ANCA immunofluorescence - prove				
A2	(0) Not specified	>>> 1	Positive	1,6 %
	(1) Fluorescent met. (ethanol)	>>> 50	Positive	78 %
	(2) Fluorescent met. (formalin)	>>> 6	Positive	9,4 %
	(99) Another measurement principle	>>> 7	Positive	11 %
----- Total per sample: n = 64 -----		Success: 100 %		
B2	(0) Not specified	>>> 1	Negative	1,6 %
	(1) Fluorescent met. (ethanol)	>>> 50	Negative	78 %
	(2) Fluorescent met. (formalin)	>>> 6	Negative	9,4 %
	(99) Another measurement principle	>>> 7	Negative	11 %
----- Total per sample: n = 64 -----		Success: 100 %		
Total success: 100 %				
(574) ANCA IF (ethanol) - semi-quantity				
A2	(0) Not specified	± 4	titre 20	7,5 %
		± 7	titre 80	13 %
		± 17	titre 160	32 %
		± 14	titre 320	26 %
		± 10	titre 640	19 %
		± 1	titre 1280	1,9 %
----- Total per sample: n = 53 -----		Success (only evaluated results):	evaluation	
B2	(0) Not specified	± 41	titre 0 (not measurable)	77 %
		± 12	titre 20	23 %
----- Total per sample: n = 53 -----		Success (only evaluated results):	evaluation	
(578) ANCA IF (formalin) - semi-quantity				
A2	(0) Not specified	± 1	Not specified	2,0 %
		± 3	titre 20	5,9 %
		± 3	titre 80	5,9 %
		± 11	titre 160	22 %
		± 23	titre 320	45 %
		± 8	titre 640	16 %
		± 2	titre 1280	3,9 %
----- Total per sample: n = 51 -----		Success (only evaluated results):	evaluation	
B2	(0) Not specified	± 40	titre 0 (not measurable)	78 %
		± 11	titre 20	22 %
----- Total per sample: n = 51 -----		Success (only evaluated results):	evaluation	
(566) ANCA - type of fluorescence				
A2	(0) Not specified	>>> 62	Cytoplasmic granular fluorescence	100 %
----- Total per sample: n = 62 -----		Success: 100 %		
B2	(0) Not specified	>>> 62	No fluorescence	100 %
----- Total per sample: n = 62 -----		Success: 100 %		
Total success: 100 %				
(569) anti-myeloperoxidase				
A2	(1) Fluorescent methods	>>> 1	Negative	1,4 %
	(2) EIA methods	>>> 52	Negative	71 %
	(5) LIA, ILMA	>>> 9	Negative	12 %
	(6) Immunoblotting	>>> 9	Negative	12 %
	(99) Another measurement principle	>>> 2	Negative	2,7 %
----- Total per sample: n = 73 -----		Success: 100 %		
B2	(1) Fluorescent methods	>>> 1	Negative	1,4 %
	(2) EIA methods	>>> 52	Negative	71 %
	(5) LIA, ILMA	>>> 9	Negative	12 %
	(6) Immunoblotting	>>> 9	Negative	12 %
	(99) Another measurement principle	>>> 2	Negative	2,7 %
----- Total per sample: n = 73 -----		Success: 100 %		
Total success: 100 %				
(570) anti-proteinase III				
A2	(1) Fluorescent methods	>>> 1	Positive	1,4 %
	(2) EIA methods	>>> 51	Positive	70 %
	(5) LIA, ILMA	>>> 9	Positive	12 %
	(6) Immunoblotting	>>> 1	Inconclusive result (borderline)	1,4 %
		>>> 8	Positive	11 %
	(99) Another measurement principle	>>> 2	Positive	2,7 %
----- Total per sample: n = 73 -----		Success: 97 %		
B2	(1) Fluorescent methods	>>> 1	Negative	1,4 %
	(2) EIA methods	>>> 52	Negative	71 %

EQA round: AIM1/22 - Autoimmunity

Test	Sample	Group	N	Result	N _{rel}	
B2		(5) LIA, ILMA	>>>	9	Negative	12 %
		(6) Immunoblotting	>>>	9	Negative	12 %
		(99) Another measurement principle	>>>	2	Negative	2,7 %
		Total per sample: n = 73		Success: 100 %		
Total success: 97 %						

Set 3

(580) Anti-ENA/SS-A/Ro-60

A3		(2) EIA methods	>>>	30	Positive	38 %
		(5) LIA, ILMA	>>>	3	Positive	3,8 %
		(6) Immunoblotting	>>>	45	Positive	56 %
		(99) Another measurement principle	>>>	1	Negative	1,3 %
			>>>	1	Positive	1,3 %
Total per sample: n = 80		Success: 99 %				
B3		(2) EIA methods	>>>	30	Negative	38 %
		(5) LIA, ILMA	>>>	3	Negative	3,8 %
		(6) Immunoblotting	>>>	45	Negative	56 %
		(99) Another measurement principle	>>>	1	Negative	1,3 %
			>>>	1	Positive	1,3 %
Total per sample: n = 80		Success: 99 %				
Total success: 99 %						

(581) Anti-ENA/SS-B/La

A3		(2) EIA methods	>>>	30	Positive	38 %
		(5) LIA, ILMA	>>>	3	Positive	3,8 %
		(6) Immunoblotting	>>>	45	Positive	56 %
		(99) Another measurement principle	>>>	2	Positive	2,5 %
		Total per sample: n = 80		Success: 100 %		
B3		(2) EIA methods	>>>	30	Negative	38 %
		(5) LIA, ILMA	>>>	3	Negative	3,8 %
		(6) Immunoblotting	>>>	45	Negative	56 %
		(99) Another measurement principle	>>>	1	Negative	1,3 %
			>>>	1	Positive	1,3 %
Total per sample: n = 80		Success: 99 %				
Total success: 99 %						

(582) Anti-ENA/Scl-70

A3		(2) EIA methods	>>>	29	Negative	37 %
		(5) LIA, ILMA	>>>	3	Negative	3,8 %
		(6) Immunoblotting	>>>	45	Negative	57 %
		(99) Another measurement principle	>>>	2	Negative	2,5 %
Total per sample: n = 79		Success: 100 %				
B3		(2) EIA methods	>>>	29	Negative	37 %
		(5) LIA, ILMA	>>>	3	Negative	3,8 %
		(6) Immunoblotting	>>>	45	Negative	57 %
		(99) Another measurement principle	>>>	1	Negative	1,3 %
			>>>	1	Positive	1,3 %
Total per sample: n = 79		Success: 99 %				
Total success: 99 %						

(583) Anti-ENA/RNP

A3		(2) EIA methods	>>>	30	Negative	38 %
		(5) LIA, ILMA	>>>	4	Negative	5,0 %
		(6) Immunoblotting	>>>	44	Negative	55 %
		(99) Another measurement principle	>>>	2	Negative	2,5 %
Total per sample: n = 80		Success: 100 %				
B3		(2) EIA methods	>>>	30	Negative	38 %
		(5) LIA, ILMA	>>>	4	Negative	5,0 %
		(6) Immunoblotting	>>>	44	Negative	55 %
		(99) Another measurement principle	>>>	2	Negative	2,5 %
Total per sample: n = 80		Success: 100 %				
Total success: 100 %						

(584) Anti-ENA/Jo-1

A3		(2) EIA methods	>>>	30	Negative	38 %
		(5) LIA, ILMA	>>>	4	Negative	5,0 %
		(6) Immunoblotting	>>>	44	Negative	55 %
		(99) Another measurement principle	>>>	2	Negative	2,5 %
Total per sample: n = 80		Success: 100 %				
B3		(2) EIA methods	>>>	30	Negative	38 %
		(5) LIA, ILMA	>>>	4	Negative	5,0 %

EQA round: AIM1/22 - Autoimmunity

Test	Sample	Group	N	Result	N _{rel}
	B3	(6) Immunoblotting	>>> 44	Negative	55 %
		(99) Another measurement principle	>>> 2	Negative	2,5 %
	Total per sample: n = 80		Success: 100 %		
Total success: 100 %					

(585) Anti-centromere antibodies

	A3	(0) Not specified	>>> 1	Negative	1,3 %
		(1) Fluorescent methods	>>> 8	Negative	11 %
		(2) EIA methods	>>> 18	Negative	24 %
		(5) LIA, ILMA	>>> 2	Negative	2,6 %
		(6) Immunoblotting	>>> 46	Negative	61 %
		(99) Another measurement principle	>>> 1	Negative	1,3 %
Total per sample: n = 76		Success: 100 %			
	B3	(0) Not specified	>>> 1	Negative	1,3 %
		(1) Fluorescent methods	>>> 8	Negative	11 %
		(2) EIA methods	>>> 1	Not specified	1,3 %
			>>> 17	Negative	22 %
		(5) LIA, ILMA	>>> 2	Negative	2,6 %
		(6) Immunoblotting	>>> 46	Negative	61 %
		(99) Another measurement principle	>>> 1	Negative	1,3 %
Total per sample: n = 76		Success: 99 %			
Total success: 99 %					

Set 4**(588) Anti-ds-DNA immunofluores. - prove**

	A4	(0) Not specified	>>> 1	Negative	1,8 %
			>>> 56	Positive	98 %
Total per sample: n = 57		Success: 98 %			
	B4	(0) Not specified	>>> 57	Negative	100 %
	Total per sample: n = 57		Success: 100 %		
Total success: 98 %					

(577) Anti-ds-DNA immunofluor. - semi-quantity

	A4	(0) Not specified	± 1	titre 0 (not measurable)	1,9 %			
			± 3	titre 10	5,8 %			
			± 1	titre 20	1,9 %			
			± 2	titre 40	3,8 %			
			± 17	titre 80	33 %			
			± 13	titre 160	25 %			
			± 9	titre 320	17 %			
			± 6	titre 640	12 %			
			Total per sample: n = 52		Success (only evaluated results): evaluation			
				B4	(0) Not specified	± 40	titre 0 (not measurable)	77 %
± 12	titre 10	23 %						
Total per sample: n = 52		Success (only evaluated results): evaluation						

(589) Anti-ds-DNA other methods

	A4	(2) EIA methods	>>> 45	Positive	80 %	
			(5) LIA, ILMA	>>> 5	Positive	8,9 %
			(6) Immunoblotting	>>> 2	Negative	3,6 %
				>>> 3	Positive	5,4 %
			(99) Another measurement principle	>>> 1	Positive	1,8 %
			Total per sample: n = 56		Success: 96 %	
	B4	(2) EIA methods	>>> 44	Negative	79 %	
				1	Inconclusive result (borderline)	1,8 %
			(5) LIA, ILMA	>>> 5	Negative	8,9 %
			(6) Immunoblotting	>>> 5	Negative	8,9 %
			(99) Another measurement principle	>>> 1	Negative	1,8 %
Total per sample: n = 56		Success: 98 %				
Total success: 95 %						

Set 5**(591) Anti-nucleosomes IgG**

	A5	(2) EIA methods	>>> 39	Positive	71 %	
			(6) Immunoblotting	>>> 1	Inconclusive result (borderline)	1,8 %
				>>> 15	Positive	27 %
Total per sample: n = 55		Success: 98 %				
	B5	(2) EIA methods	>>> 39	Negative	71 %	
			(6) Immunoblotting	>>> 16	Negative	29 %
			Total per sample: n = 55		Success: 100 %	
Total success: 98 %						

